Hikma Pharmaceuticals (HIK) Stock Forecast & Price Target

GBX 1,928 +13.00 (+0.68%)

(As of 12:05 PM ET)

Hikma Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 3 Analyst Ratings

Sell
0

Hold
1

Buy
2

Based on 3 Wall Street analysts who have issued ratings for Hikma Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 3 analysts, 1 has given a hold rating, and 2 have given a buy rating for HIK.

Consensus Price Target

GBX 2,383.33

According to the 3 analysts' twelve-month price targets for Hikma Pharmaceuticals, the average price target is GBX 2,383.33. The highest price target for HIK is GBX 2,750, while the lowest price target for HIK is GBX 2,000. The average price target represents a forecasted upside of 23.62% from the current price of GBX 1,928.

Get the Latest News and Ratings for HIK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hikma Pharmaceuticals and its competitors.

HIK Analyst Ratings Over Time

Type	Current Forecast 12/19/23 to 12/18/24	1 Month Ago 11/19/23 to 11/18/24	3 Months Ago 9/20/23 to 9/19/24	1 Year Ago 12/19/22 to 12/19/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	GBX 2,383.33	GBX 2,383.33	GBX 2,325	GBX 1,972.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

U.S. Government: “this could save civilization.” (Ad)

Experts indicate that ChatGPT alone consumes up to 17,000 times more electricity than the average U.S. household uses in a single day. And with companies like Google and Microsoft implementing AI into everything we do, that energy consumption is only going to exponentially increase. Thing is, outside of a small group of elite investors, nobody has connected the dots on how this military contractor could be the most important company in the AI boom.

To get all the details, go here now.

HIK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HIK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Hikma Pharmaceuticals Stock vs. The Competition

Type	Hikma Pharmaceuticals	Medical Companies
Consensus Rating Score	2.67	2.81
Consensus Rating	Moderate Buy	Moderate Buy
News Sentiment Rating	Neutral News See Recent HIK News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/2/2024	Berenberg Bank 2 of 5 stars	Upgrade	Buy	GBX 2,100 ➝ GBX 2,400	+20.12%
6/18/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars	Reiterated Rating	Buy	GBX 2,750	+38.05%
5/7/2024	Barclays 3 of 5 stars	Reiterated Rating	Equal Weight	GBX 2,000	+1.47%
11/13/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform	GBX 2,150	+22.16%
10/16/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
10/3/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
5/22/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	GBX 2,080 ➝ GBX 2,125	+15.46%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:18 PM ET.

HIK Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Hikma Pharmaceuticals is GBX 2,383.33, with a high forecast of GBX 2,750 and a low forecast of GBX 2,000.
: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There is currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HIK shares.
: According to analysts, Hikma Pharmaceuticals's stock has a predicted upside of 23.62% based on their 12-month stock forecasts.
: Analysts like Hikma Pharmaceuticals less than other "medical" companies. The consensus rating score for Hikma Pharmaceuticals is 2.67 while the average consensus rating score for "medical" companies is 2.81. Learn more on how HIK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why is Buffett going all in on this? (Ad)

Warren Buffett has increased his already massive stake in this sector by almost 30% in the past few months. Microsoft and Blackrock created a special fund worth $100 billion to boost this 'silent' bull market. Institutional investors have a combined $2.8 trillion in this sector. Despite its "bad rap", this industry stubbornly rakes in profits.

Click here to learn more >>>

This page (LON:HIK) was last updated on 12/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hikma Pharmaceuticals (HIK) Stock Forecast & Price Target